Compare Amgen, Inc. (AMGN) vs Marriott International Inc (MAR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Marriott International Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Marriott International Inc trades at $379.68 (market cap $99.18B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | MAR | |
|---|---|---|
Market Cap | $196.12B | $99.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $402.54 |
52-Week Low | $271.18 | $255.35 |
Enterprise Value | $241.41B | $116.13B |
Dividend Yield | 2.77% | 0.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Marriott International (MAR) trades at $376.11, up 0.98% today, with a bearish technical signal and a consensus price target of $386.42. Recent earnings show mixed results, with Q1 2026 beating expectations but Q4 2025 missing. The company maintains strong revenue growth, reaching $26.19B in 2025, and a net income margin of 9.72%. Key developments include the launch of Ask Bonvoy AI and reaching 10,000 properties globally, though hotel owners are pushing back on loyalty program terms.
Outlook is cautiously optimistic with upside to the consensus target, supported by solid fundamentals and strategic initiatives. Risks include rising debt-to-asset ratio (58.83% in 2025), competitive pressures, and potential travel demand volatility. Analyst sentiment is mixed with 44% buy ratings, but technical indicators suggest near-term bearish pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
